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Introduction
Interleukin (IL)-1β is the key proinflammatory cytokine
to trigger or promote the inflammatory responses at sites of
microbial infection or tissue injury [1]. Unlike other
proinflammatory cytokines, IL-1β contains two unique
features, including expression as the immature form pro-
IL-1β [1] and lack of the endoplasmic reticulum-targeting
leader sequence [2]. In this regard, the production of active
IL-1β requires both posttranslational maturation and
unconventional secretion to the extracellular space. It has
been well known that active caspase-1 mediates the
proteolytic cleavage of pro-IL-1β into the active form [3].
Furthermore, previous study demonstrated that caspase-1
is required for the non-classical secretion of IL-1β [4],
although the detailed mechanism of IL-1β secretion remains
to be further elucidated.
In this context, caspase-1 activation is the most critical
event for the maturation and secretion of IL-1β. Recent
studies revealed that caspase-1 is activated by the formation
of an inflammasome multiprotein complex mainly in
myeloid cells such as macrophages [5, 6]. Recognition of
microbe- or tissue damage-derived factors by inflammasome
sensor molecules, such as nucleotide-binding oligomerization
domain-like receptor family, pyrin domain-containing 3
(NLRP3), triggers assembly of the inflammasome sensor
molecule, adaptor molecule, and inactive procaspase-1 [7].
The formation of the inflammasome complex then leads
to the activation of caspase-1 by proximity-induced
autoprocessing of procaspase-1. 
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Upon sensing of microbial infections or endogenous danger signals in macrophages,
inflammasome signaling plays a significant role in triggering inflammatory responses via
producing interleukin (IL)-1β. Recent studies revealed that active caspase-1, a product of the
inflammasome complex, causes maturation of inactive pro-IL-1β into the active form.
However, the underlying mechanism by which this leaderless cytokine is secreted into the
extracellular space remains to be elucidated. In this study, we demonstrated that prolonged
lipopolysaccharide (LPS) treatment to macrophages could trigger the unexpected maturation
and extracellular release of IL-1β through a nucleotide-binding oligomerization domain-like
receptor family, pyrin domain-containing 3 (NLRP3)-independent manner. Short-term
treatment (less than 6 h) of LPS induced robust production of the IL-1β precursor form inside
cells but did not promote the maturation and secretion of IL-1β in bone marrow-derived
macrophages or peritoneal macrophages. Instead, prolonged LPS treatment (more than 12 h)
led to a significant release of matured IL-1β with no robust indication of caspase-1 activation.
Intriguingly, this LPS-triggered secretion of IL-1β was also observed in NLRP3-deficient
macrophages. In addition, this unexpected IL-1β release was only partially impaired by a
caspase-1 and NLRP3 inflammasome inhibitor. Collectively, our results propose that
prolonged exposure to LPS is able to drive the maturation and secretion of IL-1β in an NLRP3
inflammasome-independent manner. 
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In particular, NLRP3 recognizes a wide range of pathogen-
or danger signal-associated molecular patterns, including
microbial toxins and endogenous abnormal metabolites [8].
Although the detailed molecular mechanism by which
NLRP3 is activated in response to diverse stimuli is still
poorly understood, full activation of the NLRP3
inflammasome generally requires two independent signals;
a Toll-like receptor (TLR)-mediated signal 1 such as
lipopolysaccharide (LPS) for the transcriptional induction
of NLRP3, and a signal 2 such as ATP for the activation of
NLRP3 [9]. However, recent studies further revealed that
LPS, a signal 1 stimulus, induces a non-transcriptional
priming step, required for assembly of the NLRP3
inflammasome [10-12]. Additionally, it was also reported
that LPS stimulation in the absence of signal 2 could
promote the secretion of IL-1β in certain cell types, such as
dendritic cells, monocytes, and PMA-differentiated THP-1
macrophages [2, 13-15]. Furthermore, LPS administration
to mice led to a robust increase in the inflammatory
phenotype, such as serum or bronchiolar lavage fluid level
of IL-1β [16, 17]. These findings raised a possibility that
LPS stimulation alone can trigger the activation of IL-1β in
certain contexts. In the present study, we thus attempted to
examine the prolonged exposure to LPS for the maturation
and secretion of IL-1β in macrophages.
Materials and Methods
Mice
C57BL/6 and Nlrp3-/- (C57BL/6 background) mice were obtained
from Jackson Laboratory and bred at Yonsei University College of
Medicine. All mice were maintained under specific pathogen-free
conditions. Seven- to 10-week-old male mice were used for all
experiments. Protocols for the animal experiments were approved
by the Institutional Ethical Committee, Yonsei University College
of Medicine (2014-0257). All experiments were performed in
accordance with the approved guidelines of the Institutional
Ethical Committee.
Reagents and Antibodies
LPS, ATP, poly dA:dT, nigericin, and glibenclamide were
purchased from Sigma-Aldrich (USA). Ultrapure LPS was obtained
from Invivogen (USA). YVAD-chloromethylketone and z-VAD-
fluoromethylketone were purchased from Bachem (Switzerland).
Anti-mouse IL-1β antibody was obtained from R&D Systems
(USA). Anti-mouse caspase-1 (p20) and anti-NLRP3 antibodies
were from Adipogen (Switzerland). Anti-ASC antibody was
obtained from Santa Cruz (USA).
Cell Cultures
Mouse bone marrow cells were isolated from mouse femurs
and differentiated into bone marrow-derived macrophages
(BMDMs) with L929-conditioned medium. Immortalized Nlrp3-
deficient and Nlrp3-reconstituted BMDMs were provided by E.S.
Alnemri (Thomas Jefferson University, Philadelphia, PA, USA).
All BMDMs were maintained in L929-conditioned DMEM
supplemented with 10% FBS and antibiotics. Mouse peritoneal
macrophages were prepared as described below. In brief, mice
were injected with 3% BBL thioglycollate medium (BD, USA).
After 4 days, the mice were euthanized and injected with 10 ml of
cold PBS into the peritoneal cavity. The peritoneal fluid was
restored by aspiration and centrifuged, and the cell pellets were
maintained in DMEM. 
Assay of Inflammasome Activation and Cytokine Production
To induce classical activation of the NLRP3 inflammasome as a
positive control, cells were primed with LPS (0.25 μg/ml) for 3 h,
followed by treatments with ATP or nigericin. To stimulate the
absent in melanoma 2 (AIM2) inflammasome, poly dA:dT was
transfected into macrophages using Lipofectamine 2000 (Invitrogen,
USA) according to the manufacturer’s instruction. Inflammasome
activation was determined by the detection of active caspase-1 p20
and active IL-1β in culture supernatants using immunoblots, and
by quantification of extracellular IL-1β using the mouse IL-1β
Quantikine ELISA kit (R&D Systems). The level of IL-6 was
determined by ELISA (R&D Systems). 
Assay of ASC Oligomerization 
To determine the oligomerization of ASC, disuccinimidyl
suberate (DSS)-mediated cross-linking assay was performed as
described previously [18]. Briefly, cells were lysed and centrifuged
at 3,500 ×g for 10 min. The pellets were washed with PBS and then
resuspended in PBS. The resuspended pellets were cross-linked
with 1 mM DSS (Pierce, USA) for 30 min. The cross-linked
pellets and soluble lysates were fractionated by SDS-PAGE and
immunoblotted with anti-ASC antibody.
Immunoblot Analysis 
Cells were lysed in buffer containing 20 mM HEPES (pH 7.5),
0.5% Nonidet P-40, 50 mM KCl, 150 mM NaCl, 1.5 mM MgCl
2
,
1 mM EGTA, and protease inhibitors. Soluble lysates were
fractionated by SDS-PAGE and then transferred to PVDF
membranes. In some experiments, cell culture supernatants were
precipitated by the addition of a methanol/chloroform mixture as
described previously [6] and then immunoblotted. All the blots
shown are representative images of at least three-independent
experiments. Images have been cropped for presentation. 
Statistical Analysis 
All values are expressed as the mean and standard error of
individual samples. Data were analyzed using two-way analysis
of variance followed by Bonferroni post hoc testing. The level of
statistical significance was set at p ≤ 0.05. Analyses were
performed with GraphPad Prism.
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Results
Prolonged Treatment of Lipopolysaccharide Leads to the
Maturation and Secretion of IL-1β in Macrophages 
To examine whether extensive exposure to LPS alone
could drive the activation of IL-1β in macrophages, LPS
was treated into BMDMs for up to 24 h. LPS plus ATP or
nigericin treatment was used as a positive control to
stimulate NLRP3 inflammasome signaling. The 3 h
treatment of LPS to BMDMs promoted a strong production
of pro-IL-1β inside the cells, but did not promote the
secretion of IL-1β into the culture medium (Fig. 1A).
Instead, a longer exposure of LPS for more than 12 h
caused a slight secretion of matured IL-1β in the culture
supernatants of BMDMs (Fig. 1A). To exclude the
possibility that any contaminants in the LPS could induce
this unexpected release of IL-1β, we also tested the effect of
ultrapure (up)-LPS as well. Similar to LPS, prolonged
treatment of up-LPS triggered a sharp release of IL-1β in
BMDMs (Fig. 1A) and in murine peritoneal macrophages,
as determined by immunoblots (Fig. 1B). Up-LPS also
caused robust activation of IL-1β, as determined by the
presence of mature IL-1β in the culture supernatants, in
immortalized BMDMs (Fig. 1C). Of note, prolonged
treatment with up-LPS led to the release of mature IL-1β,
but not of active caspase-1, in peritoneal macrophages and
immortalized BMDMs (Figs. 1B and 1C). These findings
suggest that extensive LPS exposure is highly likely to
promote the maturation and secretion of IL-1β irrespective
of caspase-1 activation.
Prolonged Treatment of Lipopolysaccharide Causes the
Activation of IL-1β in an NLRP3-Independent Manner 
To examine whether the observed LPS-triggered activation
of IL-1β is associated with NLRP3 inflammasome activation,
we performed similar experiments in Nlrp3+/+ and Nlrp3-/-
BMDMs. Similar to Fig. 1, 12 h treatment of LPS, but not 3 h
treatment, promoted robust secretion of mature IL-1β in
the culture supernatants of NLRP3-expressing wild-type
BMDMs (Fig. 2A). Of note, this LPS-induced activation of
IL-1β was also clearly found in NLRP3-deficient BMDMs,
whereas LPS/nigericin-stimulated IL-1β secretion was
completely abolished in Nlrp3-/- cells (Fig. 2A). We also
examined this NLRP3-independent IL-1β release from
BMDMs using up-LPS. Prolonged treatment of up-LPS
clearly induced the secretion of IL-1β in NLRP3-deficient
BMDMs as well as in wild-type cells (Fig. 2B). Consistent
with this data, prolonged up-LPS treatment triggered a
considerable production of IL-1β, as quantified by ELISA,
in both Nlrp3+/+ and Nlrp3-/- BMDMs (Fig. 2C). Of note, the
secreted level of IL-1β was significantly less in NLRP3-
deficient BMDMs than that in wild-type cells (Fig. 2C).
These data raised a possibility that LPS-triggered activation
of IL-1β is partly dependent on the presence of NLRP3 in
BMDMs. Indeed, weak caspase-1 processing was found in
the culture supernatants of wild-type BMDMs upon
treatment with LPS for 24 h, but not of Nlrp3-/- cells
(Fig. 2B). Unlike IL-1β, the production of IL-6 was similar
Fig. 1. Prolonged LPS treatment triggers the release of IL-1β. 
(A) Mouse bone marrow-derived macrophages (BMDMs) were treated with LPS (0.25 μg/ml) or ultrapure-LPS (up-LPS, 0.25 μg/ml) for the
indicated times, or primed with LPS (0.25 μg/ml) for 3 h, followed by the treatment of ATP (2 mM) for 30 min. (B, C) Mouse peritoneal
macrophages (B) or immortalized BMDMs (C) were treated with up-LPS (0.25 μg/ml) for the indicated times, or primed with LPS (0.25 μg/ml) for
3 h, followed by the treatment of ATP (2 mM, 30 min, B) or nigericin (niger, 5 μM, 30 min, C). (A-C) Culture supernatants (Sup) or cellular lysates
(Lys) were immunoblotted with the indicated antibodies. Unt, untreated. Procasp 1, procaspase-1. 
118 Hong and Yu
J. Microbiol. Biotechnol.
Fig. 2. Prolonged LPS treatment promotes NLRP3-independent release of IL-1β in bone marrow-derived macrophages (BMDMs). 
(A) Nlrp3+/+ or Nlrp3-/- mouse BMDMs were treated with LPS (0.25 or 1 μg/ml) for 3 or 12 h as indicated, or primed with LPS (0.25 μg/ml, 3 h),
followed by the treatment with nigericin (5 μM, 30 min), or transfected with poly dA:dT (1 μg/ml, 6 h). (B) Nlrp3+/+ or Nlrp3-/- mouse BMDMs
were treated with ultrapure (up)-LPS (0.25 μg/ml) for 12 or 24 h. (A, B) Culture supernatants (Sup) or cellular lysates (Lys) were immunoblotted
with the indicated antibodies. (C, D) Nlrp3+/+ or Nlrp3-/- mouse BMDMs were treated with up-LPS (0.25 μg/ml) for 24 h. Culture supernatants
were assayed for the quantification of IL-1β (C, n = 3) or IL-6 (D, n = 3) by ELISA. Asterisks indicate significant differences (***p < 0.001).
Fig. 3. Prolonged LPS treatment promotes NLRP3-independent release of IL-1β in peritoneal macrophages. 
(A) Nlrp3+/+ or Nlrp3-/- mouse peritoneal macrophages were treated with ultrapure (up)-LPS (0.25 μg/ml, 12 or 24 h), or primed with up-LPS
(0.25 μg/ml) for 3 h, followed by the treatment of ATP (2 mM) for 30 min. Culture supernatants (Sup) or cellular lysates (Lys) were
immunoblotted with the indicated antibodies. (B, C) Nlrp3+/+ or Nlrp3-/- mouse peritoneal macrophages were treated with up-LPS (0.25 μg/ml) for
12 h. Culture supernatants were assayed for the quantification of IL-1β (B, n = 3) or IL-6 (C, n = 3) by ELISA. Asterisks indicate significant
differences (***p < 0.001).
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in both Nlrp3+/+ and Nlrp3-/- BMDMs upon LPS treatment
(Fig. 2D).
We also checked the implication of NLRP3 in IL-1β
activation by prolonged LPS treatment in peritoneal
macrophages. Similar to that observed in BMDMs, up-LPS
treatment caused robust secretion of mature IL-1β in wild-
type and NLRP3-deficient peritoneal macrophages
(Fig. 3A). Of interest, the LPS-driven production level of
IL-1β in Nlrp3-/- peritoneal macrophages was significantly
less than that in wild-type cells, similar to BMDMs
(Fig. 3B), suggesting that extensive exposure to LPS could
promote the activation of IL-1β through NLRP3-dependent
and -independent pathways. In addition, prolonged LPS
treatment produced a similar level of IL-6 in peritoneal
macrophages (Fig. 3C). These findings clearly support that
LPS stimulation is able to trigger, at least in part, the
NLRP3-independent maturation and secretion of IL-1β.
 
Prolonged Treatment of Lipopolysaccharide Causes
Inflammasome-Independent Activation of IL-1β 
To further examine whether prolonged LPS exposure
could activate inflammasome signaling in macrophages,
we checked for ASC oligomerization, an essential event of
inflammasome activation [19]. LPS priming followed by
Fig. 4. Prolonged LPS treatment does not induce ASC oligomerization but promotes inflammasome-independent IL-1β release.
(A) Mouse peritoneal macrophages were treated with ultrapure (up)-LPS (0.25 μg/ml, 12 or 24 h), or primed with up-LPS (0.25 μg/ml) for 3 h,
followed by the treatment of ATP (2 mM) for 30 min. Disuccinimidyl suberate-crosslinked pellets (upper panel), culture supernatants (Sup), or
cellular lysates (Lys) were immunoblotted with the indicated antibodies. (B) Mouse peritoneal macrophages were treated with up-LPS (0.25 μg/ml)
for 3 h in the presence of YVAD (20 μM) or glibenclamide (gliben, 50 μM), followed by the treatment of ATP (2 mM) for 30 min. (C) Mouse
peritoneal macrophages were treated with up-LPS (0.25 μg/ml) for 12 h in the presence of YVAD (20 μM) or glibenclamide (gliben, 50 μM). (D)
Immortalized Nlrp3-reconstituted or Nlrp3-deficient bone marrow-derived macrophages were treated with LPS (0.25 μg/ml) for 12 h in the
presence of z-VAD or YVAD (20 μM), or transfected with poly dA:dT (1 μg/ml, 6 h). (B-D) Culture supernatants (Sup) or cellular lysates (Lys)
were immunoblotted with the indicated antibodies.
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ATP, a classical NLRP3 inflammasome stimulation, promoted
robust oligomerization of ASC in peritoneal macrophages
(Fig. 4A). On the contrary, 12 or 24 h treatment of LPS
failed to induce ASC oligomerization, but drove the
secretion of mature IL-1β in peritoneal macrophages
(Fig. 4A). This observation indicates that LPS-triggered
activation of IL-1β is not associated with the assembly of
the ASC-mediated inflammasome. 
Then, we further examined the implication of the
inflammasome in LPS-triggered IL-1β activation using a
caspase-1-specific inhibitor, YVAD, or NLRP3 inflammasome
inhibitor, glibenclamide, a blocking reagent of potassium
efflux. Both YVAD and glibenclamide clearly abolished
caspase-1 activation and IL-1β secretion in peritoneal
macrophages upon LPS/ATP stimulation (Fig. 4B). However,
the secretion of mature IL-1β from peritoneal macrophages
was still evident in the presence of YVAD and glibenclamide
in response to prolonged LPS treatment (Fig. 4C), although
there was a slight decrease in IL-1β by cotreatment with
YVAD. To further provide molecular insights, we performed
similar experiments with z-VAD, a pan-caspase inhibitor.
Intriguingly, z-VAD, but not YVAD, treatment completely
abrogated the secretion of mature IL-1β from NLRP3-
expressing and NLRP3-deficient BMDMs upon stimulation
with LPS (Fig. 4D), indicating that caspases other than
caspase-1 may be involved in the LPS-triggered IL-1β
activation in macrophages. Collectively, our data propose
that prolonged LPS stimulation seems likely to induce the
maturation and secretion of IL-1β in a caspase-1- or NLRP3
inflammasome-independent manner.
Discussion
Despite the significance of the NLRP3 inflammasome
involving the pathogenesis of inflammatory and metabolic
disorders, the mechanistic basis regarding the activation of
NLRP3 remains to be further determined [20]. Initially, the
role of the TLR-engaged priming stimulus, called signal 1,
for the inflammasome activation was considered to induce
the expression of pro-IL-1β and NLRP3 [21]. However,
recent studies revealed that LPS stimulation could mediate
the posttranslational modifications of NLRP3 to facilitate
the activation [10, 11, 22]. In addition, LPS treatment alone
was shown to activate the inflammasome pathway in
certain cellular contexts [2, 13]. In this regard, we attempted
to revisit the role of LPS, a signal 1 stimulus, for activation
of the NLRP3 inflammasome, for the maturation and
secretion of IL-1β in macrophages. 
Unexpectedly, we found that extensive LPS exposure
could induce only modest activation of IL-1β in BMDMs
and peritoneal macrophages. As this LPS-driven IL-1β
activation was also found in NLRP3-deficient cells, our
results indicate that extensive LPS stimulation is able to
trigger NLRP3-independent maturation and secretion of
IL-1β in macrophages. The secreted level of IL-1β by ELISA
was significantly less in Nlrp3-knockout macrophages than
that in wild-type macrophages (Figs. 2C and 3B). These
data claim a possibility that prolonged LPS exposure also
mediates NLRP3-dependent activation of IL-1β. However,
the quantification of IL-1β by ELISA could not discriminate
premature pro-IL-1β and active IL-1β form. It is thus
possible that the reduced level of IL-1β based on ELISA in
NLRP3-deficient cells upon LPS exposure reflects less
production of pro-IL-1β rather than IL-1β. Therefore,
further studies need to be done to evaluate whether LPS
stimulation could induce NLRP3-dependent activation of
IL-1β in macrophages.
Furthermore, the potential implication of caspase-1
during LPS-triggered IL-1β activation remains to be
determined. There is likely to be a slight reduction in the
secreted level of mature IL-1β in the presence of caspase-1-
selective inhibitor YVAD (Fig. 4C). However, the maturation
and secretion of IL-1β was still observed in the presence of
YVAD, as determined by immunoblots. On the other hand,
the LPS-triggered secretion of IL-1β was completely
abrogated by pan-caspase inhibitor z-VAD. These findings
suggest that extensive LPS stimulation could promote, at
least in part, caspase-1-independent, but possibly other
caspase-mediated activation, of IL-1β in macrophages.
The underlying mechanism of LPS-promoted maturation
and secretion of IL-1β is not fully understood at present.
Intracellular LPS has been shown to promote caspase-11-
mediated noncanonical activation of caspase-1 [23, 24]. In
addition, Eltom et al. [17] showed that LPS challenge in
mice could release IL-1β in the lung via the NLRC4-
dependent, but caspase-1-, caspase-11-, and caspase-8-
independent, pathway. Moreover, a recent study presented
that LPS plus histone deacetylase inhibitors promoted the
caspase-1-independent, but caspase-8-dependent, activation
of IL-1β in dendritic cells and in macrophages [25]. To
correlate with these previous findings, future studies will
be required to clarify whether NLRC4, caspase-8, or
caspase-11 is implicated in the activation of IL-1β by
extensive LPS stimulation of macrophages. At present, our
data propose that prolonged LPS exposure in the absence
of NLRP3 agonists could potentially allow noncanonical
NLRP3- and caspase-1-independent maturation and secretion
of IL-1β.
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